Article info
PDFClinical and epidemiological research
Concise report
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
- Correspondence to Dr S H Zwillich, Pfizer Global Research and Development, 50 Pequot Avenue, New London, Connecticut 06320, USA; samuel.h.zwillich{at}pfizer.com
Citation
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
Publication history
- Accepted June 29, 2009
- First published July 8, 2009.
Online issue publication
January 26, 2010
Article Versions
- Previous version (8 July 2009).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved.